Jason J. Luke

机构：University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center · ORCID：0000-0002-1182-4908

发表论文 817 篇 · 总被引 24497 次 · h-index 64

代表论文

• Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB–IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study (2026 · The Lancet Oncology · 被引 11)
• Three-Year Update of a Randomized Phase IIb Study of the Individualized Neoantigen Therapy Intismeran Autogene (mRNA-4157, V940) Plus Pembrolizumab Versus Pembrolizumab in Resected Melanoma (2026 · JCO oncology advances. · 被引 9)
• Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors (2025 · Cancer Research Communications · 被引 5)
• Unlocking the promise of innate biology through the HLA-G/ILT2/ILT4 pathway (2026 · Journal for ImmunoTherapy of Cancer · 被引 4)
• Translating ctDNA into cutaneous melanoma care: An international expert survey (2026 · European Journal of Cancer · 被引 3)
• Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors (2026 · Journal for ImmunoTherapy of Cancer · 被引 3)